KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.

Hui Wu, Wenzhi Shu, Yongfeng Ding, Qiong Li, Ning Li, Qiyue Wang, Yinqi Chen, Yuejun Han, Dongdong Huang, Haiping Jiang

BMC Cancer 25(1) 1369

PMID40851062
PMCIDPMC12376434
DOI10.1186/s12885-025-14805-6
发表日期2025-08-24
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: Anti-programmed cell death-1 (PD-1) immunotherapy and platinum-based chemotherapy are key components of first-line treatment for advanced Gastric or Gastroesophageal Junction (G/GEJ) cancer. However, the role of immune cells infiltrating the tumor microenvironment (TME) in predicting both therapy responses is still unclear. METHODS: ORIENT-16 is a randomized, double-blind, placebo-controlled, phase 3 clinical trial, and enrolled 650 patients with unresectable locally advanced or metastatic G/GEJ cancer between January 3, 2019, and August 5, 2020. For patients enrolled from the First Affiliated Hospital of Zhejiang University School of Medicine, we analyzed progression-free survival(PFS) and overall survival (OS) based on PD-L1 expression and landmark analysis, and developed a multiplexed immunofluorescence (mIF) assay for CD4, CD8, PD-L1, CD68 and FoxP3 coupled with digital image analysis and machine learning to assess prognostic survival associations of immune cells. RESULTS: A total of 54 eligible patients were enrolled in this study, 35 received sintilimab plus platinum-based chemotherapy and 19 received placebo plus platinum-based chemotherapy. For patients with PD-L1 combined positive score (CPS) < 10, survival disparities between anti-PD-1 immunotherapy and chemotherapy emerged 300 days post-treatment. High PD-L1 expression correlated with longer survival in anti-PD-1 therapy but less benefit in platinum-based chemotherapy. The mIF analysis also demonstrated significantly higher stromal PD-L1 density in immunotherapy responders, but tended to be lower in chemotherapy responders. Besides, high tumor stromal CD8 expression could be used as a positive biomarker in anti-PD-1 immunotherapy, and high tumor stromal CD4 expression was found associated with worse prognosis in platinum-based chemotherapy. CONCLUSIONS: Increased PD-L1 expression was associated with an increased effect on anti-PD-1 immunotherapy and reduced benefit from chemotherapy. The signature of TME immune cells has the potential to predict the response of anti-PD-1 immunotherapy and chemotherapy in G/GEJ cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03745170.

KM 提取结果

3 个 Figure · 11 个 KM 面板

进入结果中心
KM Figure4 个面板

Fig. 2

Fig. 2 Kaplan-Meier plot of progression-free survival and overall survival. Progression-free survival in patients with PD-L1 CPS ≥ 10 ( A ) and PD-L1 CPS < 10 ( C ); overall survival in patients with PD-L1 CPS ≥ 10 ( B ) and PD-L1 CPS < 10 ( D ); ✴Small lesions (longest diameter < 10 mm or pathological lymph node short diameter ≥ 10 mm to < 15 mm) were taken as unmeasurable lesions. HR, hazard ratio

A

progression-free survival

Fig. 2 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:flat topline artifact
查看结果
B

overall survival

Fig. 2 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:flat topline artifact
查看结果
C

progression-free survival

Fig. 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
D

overall survival

Fig. 2 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Fig. 3

Fig. 3 Survival curves using the LANDMARK method of overall survival

Overall_Survival_Landmark_Method

overall survival

Fig. 3 · Panel Overall_Survival_Landmark_Method

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_Survival_Landmark_Method 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure6 个面板

Fig. 4

Fig. 4 Progression-free survival and overall survival subgroup analysis according to PD-L1 CPS. Progression-free survival in all randomized patients ( A ) and in patients receiving immunotherapy plus chemotherapy ( C ) and placebo plus chemotherapy ( E ). Overall survival in all randomized patients ( B ) and in patients receiving immunotherapy plus chemotherapy ( D ) and placebo plus chemotherapy ( F ). CI, confidence interval; CPS, combined positive score; HR, hazard ratio

A

Progression-free survival

Fig. 4 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Overall survival

Fig. 4 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Progression-free survival

Fig. 4 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

Overall survival

Fig. 4 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
E

Progression-free survival

Fig. 4 · Panel E

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel E 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:flat topline artifact曲线 2:extreme jump曲线 2:off origin start
查看结果
F

Overall survival

Fig. 4 · Panel F

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel F 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Trial profile ( A ) and treatment response ( B )
非 KM Figure
Fig. 5Fig. 5 The merged and single-stained images for four representative multiplex immunofluorescence (mIF) of tumor microenvironment (TME). Typical mIF images of a patient receiving sintilimab plus chemotherapy ( A ) and placebo plus chemotherapy ( D ). Immune cell infiltration levels in the tumor tissue before sintilimab plus chemotherapy ( B ) and placebo plus chemotherapy ( C ) between patients in the well-responder group and those in the poor-responder group assessed by multiplex immunofluorescence (mIF). Scale bar:100 μm
非 KM Figure